今日盘中,Arcus Biosciences(股票代码:RCUS)大涨13.38%,引发市场高度关注。
有消息指出,这次RCUS盘中大涨的主因可能来自以下两方面:首先,券商H.C. Wainwright将该股评级从"中性"上调至"买入",并将目标价从18美元大幅上调至24美元。该行分析师认为,RCUS的实验性药物casdatifan有望成为治疗一种名为"透明细胞肾细胞癌"的肾癌类型的二线疗法,看好其未来前景。
其次,RCUS刚刚公布的2025年第四季度财报数据也令投资者振奋。数据显示,该公司第四季度实现营收3600万美元,超过分析师预期的2890万美元。良好的财报数据反映出公司运营情况向好,增强了市场对该股的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.